Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06168305

Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease

Sponsor: Genoss Co., Ltd.

View on ClinicalTrials.gov

Summary

The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.

Official title: Safety and Effectiveness of GENOSS® DES (Sirolimus-eluting Coronary Stent System) in Patients With Multivessel Coronary Artery Disease (MVCAD): A Multicenter, Prospective, Observational Study

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2023-11-15

Completion Date

2028-02-28

Last Updated

2025-10-06

Healthy Volunteers

Not specified

Interventions

DEVICE

GENOSS® DES Sirolimus Eluting Coronary Stent System

The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Locations (1)

Korea University GURO Hospital

Seoul, Seoul, South Korea